Decoding Covid-19 with the SARS-CoV-2 Genome by Phoebe, Ellis et al.
BIOINFORMATICS (A PITTMAN, SECTION EDITOR)
Decoding Covid-19 with the SARS-CoV-2 Genome
Phoebe Ellis1 & Ferenc Somogyvári2 & Dezső P. Virok2 & Michela Noseda3 & Gary R. McLean1,3,4
Accepted: 29 December 2020
# The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021
Abstract
Purpose of Review SARS-CoV-2, the recently emerged coronavirus (CoV) that is responsible for the current global pandemic
Covid-19, first appeared in late 2019 in Wuhan, China. Here, we summarise details of the SARS-CoV-2 genome to assist
understanding of the emergence, evolution and diagnosis of this deadly new virus.
Recent Findings Based on high similarities in the genome sequences, the virus is thought to have arisen from SARS-like CoVs in
bats but the lack of an intermediate species containing a CoVwith even greater similarity has so far eluded discovery. The critical
determinant of the SARS-CoV-2 genome is the spike (S) gene encoding the viral structural protein that interacts with the host cell
entry receptor ACE2. The S protein is sufficiently adapted to bind human ACE2 much more readily than SARS-CoV, the most
closely related human CoV.
Summary Although the SARS-CoV-2 genome is undergoing subtle evolution in humans through mutation that may enhance
transmission, there is limited evidence for attenuation that might weaken the virus. It is also still unclear as to the events that led to
the virus’ emergence from bats. Importantly, current diagnosis requires specific recognition and amplification of the SARS-CoV-
2 RNA genome by qPCR, despite these ongoing viral genome changes. Alternative diagnostic procedures relying on immuno-
assay are becoming more prevalent.
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Introduction
In December 2019, a pneumonia illness of unknown aetiology
surfaced in Wuhan, China, with an animal meat market at the
epicentre. The causative agent was quickly discovered and
initially termed by the World Health Organization (WHO)
as the 2019 novel coronavirus (2019-nCoV). Genetic analysis
identified strong similarities between the severe acute respira-
tory syndrome (SARS) coronavirus (CoV) that was
discovered in 2003 and it was renamed SARS-CoV-2 [1, 2].
Infection with SARS-CoV-2 produces a clinical syndrome
known as 2019 novel coronavirus disease (Covid-19). The
most notable differences in SARS-CoV-2 from its predecessor
can be seen in the speed and ease with which it spreads and the
disease severity which demonstrates a reduced case fatality
rate [3]. However, unlike SARS, just 1 month after the initial
discovery, the WHO declared the outbreak of coronavirus
disease, or Covid-19, an international public health emergen-
cy and, at 11 months into the outbreak, SARS-CoV-2 has
spread worldwide and infected > 72 million people, causing
> 1.6 million deaths.1 SARS-CoV-2, like other CoVs, is
known to transmit between individuals by direct contact and
airborne mechanisms via droplets or aerosols [4]. Measures to
control such transmission such as social distancing and per-
sonal hygiene alongside a robust testing and contact tracing
system remain important to control the surging pandemic in
the absence of pharmaceutical interventions.
It is believed that genetic events occurring in animal CoVs
led to changes to the structure of the SARS-CoV-2 spike (S)
1 According to data obtained from the Covid-19 Dashboard by the Center for
Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)
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gene that altered the S protein sequence [5]. These changes
have enabled it to have a stronger affinity for the human host
cell receptor (angiotensin-converting enzyme 2, ACE2) than
the previous SARS-CoV, increasing its ability to enter cells
and replicate, ultimately facilitating improved human to hu-
man transmission [6]. ACE2 is a carboxypeptidase that con-
verts angiotensin II into angiotensin, with a counterbalancing
role in the renin-angiotensin-aldosterone system required for
cardiovascular homeostasis [7]. Its tissue distribution dictates
the infection course and subsequent pathology of SARS-CoV-
2. This review will summarise the knowledge and features of
the SARS-CoV-2 genome and how this information has been
used to understand the virus’ emergence, cell and tissue tro-
pism leading to disease, the diagnosis of infection and evolu-
tion of the virus.
Human CoVs Are Animal RNA Viruses
Grouped in the Coronaviridae Family
Human CoVs are zoonotic pathogens derived from animal
CoVs and mainly cause respiratory diseases [8]. All CoVs
have non-segmented, large single-stranded, positive-sense
RNA genomes that have a similar organisation of non-
coding untranslated regions (UTRs) and coding regions or
open reading frames (ORFs). They can be categorised into
four separate genera according to their genome and protein
sequences: alpha, beta, gamma and delta [9]. Alpha and
beta-CoVs affect humans and other mammals whereas the
gamma and delta strains affect mainly birds. There are now
seven known human CoVs: HCoV-229E (alpha), HCoV-
NL63 (alpha), HCoV-OC43 (beta), HCoV-HKU1 (beta),
MERS-CoV (beta), SARS-CoV (beta) and the most recently
discovered SARS-CoV-2 (beta). All seven human CoVs have
zoonotic origins linked to bats, mice or domestic animals [10].
Most human CoV infections are not life-threatening as infec-
tions with the 229E, NL63, OC43 andHKU1 variants produce
symptoms ranging from a mild common cold to pneumonia,
or are even completely asymptomatic. The 2003 SARS-CoV
outbreak, beginning in Guangdong, China, however, caused
severe lower respiratory tract illness, had a death rate of ap-
proximately 9% and lasted around 8 months, lingering cases
appearing in several countries worldwide until 2004, with
China, Singapore and Canada amongst the worst hit [11].
SARS is now thought of as a near-miss, from the perspective
of an emerging infectious disease that causes widespread tur-
moil. The danger of emerging human CoVs, however, was not
fully realised until the subsequent Middle East respiratory
syndrome (MERS) outbreak years later, which more than tri-
pled the mortality rate of SARS to approximately 34%. The
2012 MERS outbreak began in Saudi Arabia through human
contact with infected camels. Despite a higher death rate,
MERS-CoV does not transmit easily between humans and
most infections are seen from direct camel to human contact
[12]. Since 2012, there have been sporadic outbreaks of
MERS primarily in the Middle East and Korea, which have
resulted in over 2000 confirmed cases and approximately 700
deaths [13]. Most recently, the newest CoV to infect humans,
SARS-CoV-2, is known to transmit easily between humans in
an airborne manner then causes a range of upper and lower
respiratory tract symptoms similar to the endemic CoVs. In
addition, symptoms such as loss of sense of smell and taste,
severe cough and fever characterise infection with SARS-
CoV-2 [14]. The range of symptoms is variable however
and when severe, Covid-19 manifests as a systemic illness
characterised by hyperinflammation and cytokine storm af-
fecting multiple organs outside of the respiratory system in-
cluding the heart, kidney, liver and brain [15]. Disease sever-
ity is also variable but can be fatal for individuals with under-
lying health conditions and so-called long Covid, where fol-
lowing recovery from acute disease, many ongoing effects are
prevalent [16]. While the true death rate of SARS-CoV-2 can-
not be calculated during an ongoing pandemic, it is estimated
to be approximately 1%, with the majority of fatalities occur-
ring in individuals over 60 years old, those who are immune-
compromised or those with pre-existing conditions that are
worsened by the effects of Covid-19 disease [17].
SARS-CoV-2 Derives from Bat CoVs and Is
Closely Related to SARS-CoV
New CoVs are thought to arise from complex recombination
events when two related viral genomes are found within the
same cell—these events most often occur in non-humanmam-
mal species such as bats, resulting in progeny viruses that
acquire the ability to infect human cells [18, 19]. Thus, CoV
genomes often retain key features of their ancestral virus but
also include new features that allow for the species jump. Not
surprisingly, the genome organisation of SARS-CoV-2 is
largely similar to that of the existing human CoVs and, in
particular, to SARS-CoV which is the human CoV with the
most identity at a nucleotide level. The SARS-CoV-2 genome,
a single-stranded positive-sense RNA molecule of approxi-
mately 29,800 nucleotides, is arranged into 14 open reading
frames (ORFs) encoding 27 proteins and is shown schemati-
cally in Fig. 1 [20]. The majority of the genome contains the
ORF1a and ORF1b that encodes 16 different non-structural
proteins (nsp1-nsp16) involved in the ‘replicase’ complex al-
though many have very diverse but critical functions. The
final one-third of the genome houses several ORFs encoding
4 structural (spike, S; envelope, E; membrane, M; nucleocap-
sid, N) and 10 accessory proteins (ORF3a, ORF3b, ORF6,
ORF7a, ORF7b, ORF8a, ORF8b, ORF9b, ORF9c, ORF10).
Some of these ORFs are overlapping or found within a larger
ORF (Fig. 1a). At either end of the genome are non-coding or
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untranslated regions (UTRs) known as the 5′UTR and 3′UTR.
These UTRs are relatively short, being approximately 230
bases, but have important regulatory functions [21]. The 5′
UTR is highly structured and thought to contain 5 stem-loop
(SL1–SL5) structures, with the SL3 structure also housing the
transcriptional regulation sequence (TRS-L) important for
generation of subgenomic mRNAs [22]. Each gene in the
genome also has its own upstream TRS-B sequence. The 3′
UTR is equally important in CoV replication containing con-
served and hypervariable bulged stem-loop (BSL) structures
that may function as molecular switches [23]. Another critical
RNA structure between ORF1a and 1b is predicted to exist
that allows ribosomal frameshifting [23]. This stem-loop
structure may form a pseudoknot that creates a so-called slip-
pery sequence allowing a translational shift of frame, thought
to be necessary for the correct translation of the nsp12 or
RNA-dependent RNA polymerase (RdRp)—the viral enzyme
critical for the genesis of new genomic material.
We performed phylogenetic analyses of all seven humanCoV
full-genome reference sequences that revealed that the endemic
CoVs (229E, NL63, HKU1, OC43) are more closely related to
each other and diverge from the newest three CoVs (MERS,
SARS1, SARS2), which also cluster together (Fig. 1b). At the
genome level, SARS-CoV-2 is 96.75% similar to a bat CoV,
known as RaTG13, but its nearest human CoV relative is
SARS-CoV at just 86.85% similar (Fig. 1c). A complete genome
identity matrix for all seven human CoVs revealed that SARS-
CoV-2 is less similar to the remainingCoVs, includingMERS, at
approximately 80% identity (Fig. 1c).
The closest relative of SARS-CoV-2 has long been thought
to be the bat CoV RaTG13 (reported to be discovered in
2013), but the genome sequence was made publicly available
only in March 2020, well after the Covid-19 pandemic begin-
nings [24]. Although several bat CoVs were discovered in
Wuhan, China, and reported in 2017, the name RaTG13 does
not feature in the literature, until 2020 [25]. For optimal zoo-
notic transfer to humans, an intermediate species of CoV,
more closely related to SARS-CoV-2, should exist, although
the pangolin has been suggested as one possibility due to
genetic similarity to SARS-CoV-2 of a specific CoV, isolated
from sick animals [26]. Here, SARS-CoV-2 would require
selection and adaptation to bind a human-like ACE2 and in-
deed both RaTG13 and a recently identified pangolin corona-
virus (Pangolin-CoV-2020) have been demonstrated to bind
human ACE2 [27]. Chinese horseshoe bats are natural reser-
voirs of SARS-like CoVs that enter cells using ACE2 and
these would usually require an intermediate species before
adapting to infect humans [28]. Surprisingly, the S protein
of the RaTG13 strain was found to be unable to bind to the
ACE2 receptor of two different types of horseshoe bats, de-
spite being the suspected natural host species [29]. RaTG13,
discovered from a faecal sample of a horseshoe bat
Rhinolophus affinis, has 96.75% homology with SARS-
CoV-2 and there is no other reported CoV of higher similarity.
A
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Fig. 1 Human CoV genome organisation and relationships. Schematic of
SARS-CoV-2 genome based on NCBI sequence MT786327 (severe
acute respiratory syndrome coronavirus 2 isolate SARS-CoV-2/human/
TUR/Kafkas-SARSCoV2-001/2020, complete genome, 2020) (a). The
genome is shown with ORFs boxed in colour below the nucleotide
numbering. The region from ORF1a to ORF1b (nucleotides ~ 233–~
21,531) is expanded below to resolve nsp1–nsp16. Phylogenetic tree of
human CoVs and closest bat CoV (RaTG13) created by Kalign (EMBL-
EBI) (https://www.ebi.ac.uk/Tools/msa/kalign/) (b). NCBI reference
sequences accession numbers: SARS-CoV-2 (MT786327); SARS-CoV
(NC_004718); MERS-CoV (NC_019843); HKU1 (NC_006577); OC43
(NC_006213); 229E (NC_002645); NL63 (NC_005831). Percent
identity matrix of full-genome sequences produced by Clustal2.1
alignment of EMBL-EBI Kalign output (c)
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The S ORF of RaTG13 is 94.9% identical to that of SARS-
CoV-2 (Fig. 2a). Speculation of a non-zoonotic origin has
been spurred by the inability to find an intermediate strain of
higher homology and the reported appearance of the RaTG13
sequence after the SARS-CoV-2 outbreak had already started.
Thus, arguments exist that challenge the zoonotic origin of
SARS-CoV-2 and, instead, suggest that the virus may not
have a natural origin. A report investigating features of the
virus genome that do not align with common aspects of
CoVs evolution speculates that the bat coronaviruses ZC45
and ZXC21 (ZC45 GenBank accession MG772933.1;
ZXC21 GenBank accession MG772934.1; both sequences
submitted January 5, 2018) could have been used as a back-
bone for the genetic engineering of SARS-CoV-2 [30]. Here,
it is noted that ZC45 and ZXC212 share approximately 86%
similarity with SARS-CoV-2 and would require minimal
modifications to create the novel CoV [31]. Unusual features
highlighted in support of this are the high conservation of
ORF8 and E between ZC45/ZXC21 and SARS-CoV-2.
ZC45/ZXC21 shares 94.2% identity with the SARS-CoV-2
ORF8 and no other CoVs share more than 58% identity with
SARS-CoV-2 on this particular protein [31]. A 2017 analysis
of various SARS-related bat CoVs not only acknowledges the
high variability of ORF8 but also reports that ORF8 is highly
conserved between the human SARS-CoV and a closely re-
lated bat CoV [25]. Therefore, this high conservation is not
entirely unheard of in natural settings. The E sequence is
100% identical between ZC45/ZXC21 and SARS-CoV-2,
even though this small structural protein is tolerant of amino
acid substitutions [31]. Evidence also suggests that the SARS-
CoV-2 E sequence is changing throughout the pandemic [31]
albeit at a low frequency [32]. Finally, it has been speculated
that the S protein of SARS-CoV-2 may have been manipulat-
ed. The successful engineered swapping of the S receptor-
binding motif (RBM) of SARS-CoV, a region of S that is
critical for ACE2 recognition, with several closely related
bat coronaviruses in 2008, allowed modification of the S pro-
tein to interact with the ACE2 entry receptor [33].
Interestingly, the SARS-CoV-2 S ORF contains two unique
restriction sites EcoRI (gaattc) and BstEII (ggttacc) flanking
the RBM sequence that are not present in other human CoVs
(HKU1, OC43, MERS, SARS-CoV) and could facilitate such
engineering. It is striking that the RaTG13 S ORF contains the
identical EcoRI and BstEII restriction sites. However, the full
SARS-CoV-2 genome sequence contains 9 EcoRI and 4
BstEII sites, rendering these not unique.
The origin of SARS-CoV-2 remains an area of intense
investigation considering the scope of the pandemic. Efforts
to understand its evolution via an intermediate species remain
at the forefront and would require recombination events be-
tween two CoVs, whereby a S RBM with improved affinity
for human ACE2 was present. Andersen et al. [5] argue that
the RBM of SARS-CoV-2 contains substituted amino acids
diverging from SARS-CoV that indicate ‘the high-affinity
binding of the SARS-CoV-2 spike protein to human ACE2
is most likely the result of natural selection on a human or
human-like ACE2 that permits another optimal binding solu-
tion to arise’. The authors propose the origin of SARS-CoV-2
as either (1) natural selection in an animal host before zoonotic
transfer and (2) natural selection in humans following zoonot-
ic transfer [5]. Until an intermediate CoVwith the key features
of the S gene found in SARS-CoV-2 is discovered, these
proposals and the unnatural origin theory are impossible to
prove or disprove.
The SARS-CoV-2 Spike Protein Determines
Cell and Tissue Tropism
The S ORF of human CoVs encodes the critical S protein that
covers the surface of the viral particle and facilitates entry into
cells. The S protein sequence has high homology to that of
RaTG13 (94.9%) and also to SARS-CoV (84.74%); therefore,
the SARS-CoV-2 S is well-adapted to bind human ACE2.
SARS-CoV-2 has high affinity for human ACE2 which is
the entry receptor [6]. Homology with the remaining human
CoVs that do not bind ACE2 and use a variety of different
entry receptors is not surprisingly lower (Fig. 2a). S is a large
protein of over 1200 amino acids that can be broken down into
two subunits S1 and S2 by host cell enzymatic cleavage. The
S1 subunit is the most external region and determines interac-
tion with ACE2 through its RBM (Fig. 2b). Alignment of the
SARS-CoV-2, SARS-CoV and RaTG13 RBM demonstrate
homologous regions that specify interaction with ACE2
(Fig. 2c). To infect cells, SARS-like CoVsmust first bind with
ACE2 on the surface of cells followed conformational chang-
es which precedes membrane fusion events and uptake of the
virus into cells [34]. This interaction between SARS-CoV-2
and ACE2 defines the cells and tissues that the virus can infect
and subsequent pathology.
Cellular entry of SARS-CoV-2 depends not only on the
binding of the S protein to ACE2 but also on the subsequent
S protein priming by cellular proteases, in particular
TMPRSS2 and cathepsin B/L activity which in vitro can sub-
stitute for TMPRSS2 [35]. ACE2 and TMPRSS2 have been
detected in both nasal and bronchial epithelia by immunohis-
tochemistry [36]. Single-cell transcriptomics datasets from
different tissues, including those of the cornea, retina, respira-
tory tract, oesophagus, ileum, colon, heart, skeletal muscle,
spleen, liver, placenta/decidua, kidney, testis, pancreas, pros-
tate gland, brain and skin, have been used to map the expres-
sion of ACE2 and TMPRSS2 genes [37, 38]. Notably,
2 An NCBI Blast search of ZXC21 reveals 100% coverage and 97.48% iden-
tity to ZC45 with the remainder of hits being SARS-CoV-2 clinical isolates
with 91–95% coverage and 88.67% identity.
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although the absence of gene expression should be interpreted
with caution as analysis of single-cell transcriptomics may
lack specific cell types due to their rarity, to the limitations
of cell isolation protocols, methods of analysis and dropout
effects, detection of ACE2 and TMPRSS2 is highly reliable.
ACE2 is detected in cells of many tissues, including the cor-
nea, respiratory tract, heart, kidney and testis, along the diges-
tive tract in the oesophagus, ileum, colon and in accessory
digestive organs—liver and gallbladder. Some cells co-
express both ACE2 and TMPRSS2 such as cells of the cornea
and of the airways. Interestingly, TMPRSS2 expression shows
a broader distribution suggesting that ACE2 may be a limiting
factor for viral entry [38]. Specifically, co-expression of
ACE2/TMPRSS2 in nasal goblet and ciliated cells implicates
their potential importance as entry sites and reservoirs for
SARS-CoV-2. Notably, although gene expression data clearly
show nasal ACE2 mRNA expression, detection of its protein
is less clear [36, 38, 39]. The co-expression in conjunctival
cells could also imply a putative spread through the
nasolacrimal duct and it explains ocular symptoms observed
in some Covid-19 patients [40]. The concomitant presence of
ACE2 and TMPRSS2 transcripts in cells of the oesophagus,
ileum and colon could explain viral faecal shedding previous-
ly reported [41] and suggests a potential faecal-oral transmis-
sion of SARS-CoV-2, which so far does not have other
support.
SARS-CoV-2 Spike ORF Contains a Unique
Insertion Encoding a Furin Cleavage Site
After receptor interaction through the S glycoprotein, CoVs uti-
lise diverse host cell proteases for cleavage activation of virus-
host cell membrane fusion and subsequent genome delivery.
Inspection of the SARS-CoV-2 genome reveals the presence of
a furin cleavage site at the S1/S2 junction of the S protein that is
not found in other beta-CoVs of any species. This is achieved by
a 12-base insertion (cctcggcgggca) encoding PRRA amino acids
(Fig. 2d). Protease cleavage of the S protein is necessary for
initiating host cell invasion after ACE2 attachment and is usually
achieved by the S2’ cleavage site that is catalyzed by the host cell
serine protease TMPRSS [35]. Dual-protease cleavage of SARS-
CoV-2 spike would therefore provide a fusion and entry advan-
tage over that of related human CoVs, potentially priming S for
optimal conformation and entry receptor interaction that could
enhance replication and transmission. This concept is not without
precedent, as manipulation of a porcine CoV enabled researchers
to alter the trypsin-dependent protease cleavage site to be activat-
ed instead by furin, which enhanced infectivity of target cells
[42]. Although this suggests furin cleavage can be synthetically
engineered, a separate study of proteolytic cleavage in the
MERS-CoV spike protein emphasises that MERS-CoV is capa-
ble of adapting to various conditions and cleavage can be acti-
vated by either trypsin or furin proteases. Furin cleavage motifs
were identified at S1/S2 and S2’ in MERS both by sequence
alignment and a furin cleavage prediction algorithm [43]. This
adaptability contradicts theories of genetic manipulation of the
spike protein cleavage site, as SARS-like CoVs may have al-
ready been readily capable of naturally switching to furin-
activated cleavage.
Diagnosis of SARS-CoV-2 Infection
Detection of SARS-CoV-2 infection can be performed by two
complementary methods: (1) detection of the virus itself (pro-
tein or RNA) in mostly upper respiratory tract samples or (2)




Fig. 2 CoV spike protein ORF and sequence details comparisons.
Percent identity matrix of spike ORF sequences produced by Clustal2.1
alignment (a). Based on NCBI sequence MT786327 (severe acute
respiratory syndrome coronavirus 2 isolate SARS-CoV-2/human/TUR/
Kafkas-SARSCoV2-001/2020, complete genome, 2020). CoV spike
sequences based on information within Fig. 1. Schematic view of
SARS-CoV-2 spike protein domains (b). Numbering according to
amino acid position. Receptor-binding domain (RBD, blue), receptor-
binding motif (RBM, green), spike subunits (S1 and S2) generated by
enzymatic cleavage (furin site and S2’ cleavage). Alignments of the spike
RBM (c) and S1/S2 junction amino acids showing furin polybasic
recognition site (d) (green residues) of SARS-CoV-2, SARS-CoV and
RaTG13 as created by Kalign (EMBL-EBI) (https://www.ebi.ac.uk/
Tools/msa/kalign/). Critical residues for ACE-2 receptor interaction are
displayed in red and conserved residues boxed in grey
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IgM and/or IgG antibody responses. In the acute phase of the
infection, due to the time required to induce the adaptive im-
mune response, the serological methods have lower sensitivity.
Therefore, after the first SARS-CoV-2 genome sequence
(Wuhan-Hu-1, GenBank accession number MN908947) was
made available in January 2020 (https://virological.org/t/
novel-2019-coronavirus-genome/319), a variety of molecular
diagnostic tests have been developed to detect the viral
genome. RT-PCR is therefore routinely used to diagnose cur-
rent infection by detecting parts of the SARS-CoV-2 RNA
genome. Swabs are taken from the nose or throat, followed
by extraction of RNA and downstream processing using com-
mercially available reagents, eventually making use of specific
primer-probe sets to quantitate the viral RNA [44, 45].
According to the FIND database which collects the descriptions
of commercially available or in development SARS-CoV-2
diagnostic assays, as of 29 September 2020, there were 853
assays in the database with 377 described to target the SARS-
CoV-2 genome (https://www.finddx.org/covid-19/pipeline/).
Besides the most commonly available PCR-based and quanti-
tative PCR (qPCR)–based methods, other methods such as
loop-mediated isothermal amplification (LAMP),
transcription-mediated amplification (TMA), clustered regular-
ly interspaced short palindromic repeats (CRISPR)–based as-
says, rolling circle amplification, microarray and metagenome
sequencing are theoretically available [46]. Despite the avail-
ability of various detection methods, a review of 112 molecular
detection assays showed that 90% are based on PCR, 6% are
based on isothermal amplification technologies (e.g. LAMP
and TMA), 2% are based on hybridisation technologies and
2% utilise CRISPR-based technologies [46]. Amongst the
PCR methods, qPCR is the most commonly used due to the
shorter assay time (no need for gel electrophoresis), higher sen-
sitivity and higher specificity (two primers and a probe com-
pared to two primers in a conventional PCR). Several problems
arise regarding PCR-based detection of SARS-CoV-2 genome.
First, SARS-CoV-2 is an RNA virus; therefore, the RNA
should be reverse transcribed into a cDNA that would serve
as a template in PCR. The reverse transcription (RT) step can
be performed before the PCR, or there is a one-step possibility
when the RT step and the PCR step are performed in the same
tube. The one-step method requires no transfer between the RT
tube and the PCR tube decreasing the chance of contamination.
The second problem is the fact that most of the PCR-based
detection methods detect more than one SARS-CoV-2 gene.
The US Centers for Disease Control and Prevention (CDC)
recommended RT-qPCR method containing primers and
probes for two regions of the SARS-CoV-2 nucleocapsid gene
(N1 and N2) and also for one region of the human RNase P as a
positive control for RNA extraction and lack of inhibition in the
qPCR. The CDC assay is considered positive when both N1
and N2 singleplex qPCR assays are positive; otherwise, the
result is not conclusive. The World Health Organization
(WHO) recommends primer and probe sets for the E and the
RdRp genes. First, the E gene is tested, and positivity is con-
firmed by a separate RdRp qPCR. Additional confirmation is
based on the detection of the N gene [47].
Themost streamlined approachwould be a one-stepmultiplex
RT-qPCR assay that performs the RT and identifies several
genes in the same reaction. Examples of multiplex RT-qPCRs
include the QIAstat-Dx Respiratory SARS-CoV-2 panel
targeting the E and RdRp genes, the TaqPath Covid-19 combo
targeting the ORF1b and N and S genes, and the Allplex 2019-
nCoV assay targeting the E, N andRdRP genes [46]. The need to
detect more than one viral gene sequence is related to the muta-
tion of the viral genome that potentially renders these sequence-
based detection methods less usable (lower sensitivity) or unus-
able (lack of inclusivity) due to primer and/or probe mismatches.
The genomic mutation rates for RNA viruses are generally
higher than for the DNA viruses [48]; however, the RNA poly-
merase of CoVs in cooperationwith the non-structural protein 14
(nsp14) contains proofreading activity; therefore, the mutation
rate of CoVs is lower. The estimated evolutionary rate of the
SARS-CoV-2 is 2.24 × 10−3 substitutions/site/year [49] and anal-
ysis of 28,726 SARS-CoV-2 whole genome sequences found
7823 SNP profiles with 4968 single mutations in SARS-CoV-2
isolates originating within the USA [50]. Several studies exist
linking genomic changes to diagnostic sensitivity. In one such
study, 39 primer and probe sequences used in SARS-CoV-2
diagnostic qPCRs were mapped to 30 Colombian SARS-CoV-
2 sequences [51]. 5 nucleotides (primers or probes) showed mis-
matches with at least one Colombian SARS-CoV-2 sequence.
Examples include theCorman-Berlin (2020) RdRPSARSr assay
forward primer, which had amismatch in oneColombian SARS-
CoV-2 sequence located in a 3′ region and strongly influenced
the binding of the primer and subsequent DNA extension. The
reverse primer of the same assay also had a mismatch in all the
included Colombian SARS-CoV-2 sequences, but it was located
at an internal site of the primer andmay not influence the binding
significantly. The 20-nucleotide Hong Kong (2020) HKU-NP
probe had 4 nucleotide mismatches with all of the Colombian
sequences potentially leading to inefficient binding and false-
negative results. The forward primer of the Zhu 2020 CDC-
China Set II had a significant GGG➔AAC mismatch in three
Colombian SARS-CoV-2 sequences, while the 3′ end of the
same primer contained a single nucleotidemismatch in 2 genome
sequences. In another study, primer-probe sequences of 8 com-
monly used SARS-CoV-2 qPCR tests were compared to 15,001
SARS-CoV-2 genome sequences [52]. 12 primer-probe sets cov-
ered over 98% of SARS-CoV-2 genomes without mismatches.
Reverse primers of two primer-probe sets contained a single
mismatch in over 99% of genomes. Forward primer of the
China CDC assay showed mismatches against 23 SARS-CoV-
2 genomes with up to 8 nucleotide mismatches. Similarly, to the
previously mentioned Colombian data, the forward primer of the
China CDC assay showed a trinucleotide mismatch
Curr Genet Med Rep
GGG➔AAC in one of the SARS-CoV-2 genome variants. This
variant was detected first in February 2020 and by June 8, 2020,
was presented in 18.8% of the analyzed SARS-CoV-2 genomes.
Altogether, the dynamic changes in the SARS-CoV-2 genome
and the emergence of new virus clades direct us to assess geno-
mic detection results with caution. Inconclusive results or nega-
tive results with the presence of typical clinical symptoms require
repeating the diagnostic qPCR with another sample or
performing the diagnostic qPCR with another assay targeting
different regions of the SARS-CoV-2 genome.
Genetic Divergence of SARS-CoV-2
from SARS-CoV and Diagnostic
Considerations
As outlined earlier, the diagnosis of current SARS-CoV-2 infec-
tion is largely performed by qRT-PCR amplification of virus-
specific sequences although serological testing can confirm evi-
dence of current and past infection [53]. The challenge in qRT-
PCR diagnostic testing of SARS-CoV-2 is therefore to target a
region of the genome that is both different enough from other
CoVs to be distinguishable, yet reliably stable despite mutation
accumulation. Critically, the diagnostic test must be compatible
with the vast majority of Covid-19 cases, regardless of geograph-
ical mutation differences. The primer-probes used to distinguish
SARS-CoV and SARS-CoV-2 are important considering the
genome similarity between the two CoVs [1]. As described
above, many primer-probe mixtures are currently in use for di-
agnosis of SARS-CoV-2 by qRT-PCR.While the sensitivity and
selectivity of each mixture can vary, there are more than a dozen
combinations with proven specificity and sensitivity in laborato-
ry settings. A comparison of ten primer-probe sets by a Korean
research team identified 2019-nCoV_N2, N3, developed in the
USA, and NIID_2019-nCOV_N, developed in Japan, as the
most sensitive primer-probe sets for targeting the N gene.
Another set, ‘ORF1ab’ from China, was determined to be the
most sensitive primer-probe mixture for targeting the RdRp re-
gion of the SARS-CoV-2 genome [54]. Researchers inferred that
a combination of these primer-probe sets would yield the best
selectivity and sensitivity for diagnostic testing. The reliability
and variety of primer-probe sets that target the N gene are in
agreement with the use of the antibody tests which detect anti-
N antibodies as a means of identifying if an individual has been
previously exposed to SARS-CoV-2 [55]. This further supports
the concept that the N region of the genome is both unique and
reliably stable despite the evolution of the virus as it spreads.
Another analysis of seven different primer-probe sets at the
University of Washington Clinical Virology Lab found that as-
says using N2 and a set targeting the E gene, known as ‘Corman
E gene’ primer-probe set, were the most sensitive for SARS-
CoV-2, although all primer-probe sets being analyzed showed
high specificity and none exhibited cross-reactivity or false
positives [56]. The location of the 2019-nCoV_N2, ORF1ab
and Corman E gene probes in the SARS-CoV-2 reference ge-
nome is indicated in Fig. 3. For comparison purposes, the probes
illustrated for SARS-CoV correspond to the same proteins as
those illustrated for SARS-CoV-2. These are the N probe, 1b
probe and E probe. However, there are also several reliably sen-
sitive primer-probe sets for the detection of SARS-CoV, includ-
ing those that can target regions of the spike ORF and other
structural proteins ORFs. Several SARS-CoV-2 primer-probe
sets whose nucleotide location could be identified at the time of
this report have also been listed in Fig. 3.
SARS-CoV-2 Genome Mutation Analysis
RNA viruses routinely accumulate mutations and changes in
their genome sequence as a result of polymerase infidelity
[48]. SARS-CoV-2 is no different but incorporates proofread-
ing activity as outlined above to minimise nucleotide muta-
tion. A regularly updated phylogenetic tree of SARS-CoV-2 is
publicly available at Nextstrain.org [57] and is displayed in
Fig. 4. Transmission of the virus over time is represented by
branching, with interactive nodes indicating reported sample
genomes and mutational events. Branching between nodes is
hypothesised based on genomic similarities and region. The
changes in colour indicate the spread to different continents as
genetic drift causes a gradual divergence of the viral gene
pools based on an infected individual’s geographic location.
A comparison of the original SARS-CoV-2 Wuhan reference
genome with genomes compiled from the worldwide sample
datasets depicts areas of highest variability. Tracking muta-
tions and variable regions is critical for the development of
effective therapeutics as genetic diversity can have implica-
tions towards drug resistance. It can be readily seen in Fig. 4a
that the SARS-CoV-2 genome accumulates numerous muta-
tions over time and that these genotypes are distributed in a
unique fashion globally (Fig. 4a). Some individuals may con-
tract SARS-CoV-2 in a geographical region that has different
accumulated mutations from other parts of the world, and
these mutations may occur in critical parts of the genome.
Other mutations will have little to no effect on viral replication
and transmission but will accumulate over time and become a
molecular marker of virus spread geographically. Given that
the pandemic is still ongoing, and mutations will continue to
accumulate and branch off from the original reference ge-
nome, this is a dynamic and variable process that will deter-
mine features of the virus pandemic. Figure 4c, also obtained
from Nextstrain.org, demonstrates that mutations have
accumulated across the SARS-CoV-2 genome with hotspots
frequently found within ORF1b, S and N genes. The accumu-
lated mutations have led to geographically different viral gene
pools, seen by the differences in colour shown in Fig. 4a, b. It
is possible that Covid-19 could become a seasonal disease,
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with peaks in cases occurring annually. This effect would
imply that either the virus mutates quickly and attenuates itself
or could evade our immunity by genetic drift similarly to
influenza virus. Neither outcome can be determined during
the ongoing pandemic, but they are important concepts to
consider given that the former path would herald an end to
the pandemic and the latter would require constant adaptation
of diagnostic tests and updated vaccine preparations to be
generated.
Another concept, considering the prevalence of virus vari-
ants, is that re-infection following recovery could be possible.
One such event has been documented and showed that the
genome sequence of the virus strain in the first episode of
Covid-19 infection was clearly different from that of the virus
strain found during the second episode of infection [58]. Here,
a young and healthy patient had a second episode of Covid-19
infection diagnosed 4.5 months after the first episode. Viral
genomes from first and second episodes belonged to different
Fig. 3 SARS-CoV and SARS-CoV-2 genomes schematic displaying
diagnostic RT-PCR primer-probe sets. The SARS-CoV genome (a) and
SARS-CoV-2 genome (b) schematics showing positions of important
RT-PCR primer-probe sets for diagnostic analysis (red lines).
Additional SARS-CoV-2 primer-probe sets and their genome location
are displayed in (c)
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lineages and 24 nucleotides were different between the virus-
es. Amino acid changes were identified in 9 viral proteins and
included a large truncation of ORF8 protein that was present
only in the virus from the first infection. This case demon-
strates that not only is re-infection with SARS-CoV-2 possible
but also that virus mutation could drive this process to avoid
pre-existing protective immunity.
As transmission and global spread of SARS-CoV-2 has
increased, many accumulated mutations have prevailed (Fig.
4a). Mutations that either strengthen the virus’ infectivity or
replication, or those that do not detrimentally affect the func-
tion of the virus, are most likely to be passed on. One such
mutation at position 614 of the spike protein that changes the
encoded amino acid from aspartic acid to glycine, known as
mutation D614G, has been found to increase SARS-CoV-2
infectivity of ACE2 expressing cells [59] and has become the
prevalent virus variant in the pandemic [60, 61]. The mecha-
nism behind this enhancement is understood to be a result of
decreased S1 shedding when S protein is cleaved at the S1/S2
junction. A single virion with more S proteins that have not
shed the S1 subunit can, therefore, result in a greater likeli-
hood for functional S proteins to encounter ACE2 for attach-
ment. This concept has been proved experimentally in vitro
using a leukaemia virus pseudotyped with G614 SARS-CoV-
2 S genes, resulting in 9 times greater infectivity and de-
creased S1 shedding than of those containing D614 S proteins
[62].
A common mutation at position 314 of ORF1b affects the
RdRp complex, which is encoded by nsp12. Mutations to the
RdRp complex are rarely viable since it is responsible for
transcription processes and its structure is highly conserved
across both SARS-CoVs. The mutation identified at codon
314 results in an amino acid change from proline to leucine
and has been observed to increase mutation rate incidences
[63]. Proline is associated with flexibility and leucine with
stabilisation in proteins; thus, increased rigidity in the overall
RdRp structure due to the leucine introduction may result in
poorer interactions with unwinding RNA, leading to a higher
rate of transcription error, an effect confirmed by structural
analysis of the molecular flexibility of a mutated RdRp mol-
ecule [64]. As can be expected, the emergence of the RdRp
mutation in February 2020 led to increased subsequent muta-
tions, including those in spike and the nucleocapsid, such that
these alterations tend to exist simultaneously [65].
Mutations in N resulting in two amino acid substitutions,
arginine to lysine, and glycine to arginine at positions 203 and
204, have also been documented [65]. These genomic changes
have been associated with decreased microRNA (miRNA)
binding, which can result in a higher susceptibility to infec-
tion. Host miRNA binding at sites of infection can limit in-
vading viral pathogens before a successful infection has been
established [66].
In addition to these point mutations accumulating in the
SARS-CoV-2 genome, there are several documented larger
genomic deletions that have occurred during the pandemic.
Since CoV genome evolution is driven by a series of recom-
bination events and incremental adaptive mutations, the ap-
pearance of more dramatic genomic variants is not surprising.
Deletions within the spike gene resulting in short losses of
amino acids that can attenuate SARS-CoV-2 have been found
[67–69] and suggest that the S gene allowing human infection
may be under strong selective pressure. Considering the large
proportion of asymptomatic cases that are observed in the
pandemic, screening such individuals for the presence of S
deletion mutants would be of interest. Additionally, it is likely
that S deletion mutants might make useful attenuated vaccine
Fig. 4 Genomic epidemiology of SARS-CoV-2—global subsampling.
Screenshots of SARS-CoV-2 genome mutation (a), variation globally
(b) and regions of frequent mutation are demonstrated as bars within
the SARS-CoV-2 genome schematic (C). Images were downloaded
from https:nextstrain.org/ncov/global on 24 September 2020 showing
4640 genomes sampled between December 2019 and September 2020
(last updated 18 September 2020)
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candidates. Further deletion mutants have been described in
nsp1 [70], ORF7b [71] and ORF8 [72], but overall, these are
much rarer events than single point mutations.
Concluding Remarks
SARS-CoV-2, a recently emerged CoV responsible for the
current global pandemic Covid-19, first appeared in late
2019 in Wuhan, China. The virus is thought to have arisen
from SARS-like CoVs in bats due to high similarities in ge-
nome sequence which are also shared with the prior SARS-
CoV. The SARS-CoV-2 genome retains many features of
endemic human CoVs but the critical determinant, the S pro-
tein, is sufficiently adapted to bind the human entry receptor
ACE2 much more readily than SARS-CoV which is the most
closely related human CoV. There is evidence that the viral
genome is undergoing subtle evolution through mutation to
enhance transmission and there is evidence for limited atten-
uation that might weaken the virus. The scientific and medical
community has mobilised in an unprecedented fashion to un-
derstand the virus at molecular and epidemiological levels,
determine its pathological consequences, understand protec-
tive immunity and develop specific antivirals, vaccines and
other treatments. However, as of writing, the pandemic is
yet to be fully under control although some territories have
had success. Currently, the only effective measures to restrict
viral transmission are limiting social interactions, mass diag-
nostic testing and contact tracing applications. Further under-
standing of the genetics behind the virus’ emergence and
mechanisms of replication will be critical to generate specific
therapeutics and protective vaccines to halt the continued
spread. This knowledge will also assist and limit the future
potential for new CoVs to emerge.
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